Dren Bio has generated a broad and diverse pipeline that encompasses
multiple clinical and
preclinical programs. Both Dibotatug and the Targeted Myeloid Engager and Phagocytosis
Platform
were developed by leveraging Dren Bio’s deep expertise in immunology
and protein engineering.
1. Press Release: Sanofi completes acquisition of DR-0201 (May 27, 2025)
Dibotatug (DR-01; Selective Autoreactive Cell Depletion)
DR-01 is a first-in-class, fully human monoclonal antibody targeting CD94,
pathogenic cytotoxic cells while preserving the broader immune system.
DR-01 is currently being evaluated in patients with cytotoxic T-cell lymphoma (CTL)
a rare aggressive blood cancer with poor prognosis and large granular lymphocytic
leukemia (LGLL), a rare chronic hematologic malignancy that can cause severe
neutropenia, anemia and transfusion dependence. Both diseases have significant unmet
medical needs and no approved therapies.
DR-0202 Program
DR-0202, is a first-in-class
bispecific antibody that
harnesses myeloid cells to selectively deplete cancer cells by targeting a cell
surface receptor
that is highly expressed in various solid tumors. By leveraging myeloid cells to
deplete tumor
cells and subsequently cross-present antigens, DR-0202 primes the adaptive immune
system to
potentially elicit deep and durable responses.
DR-0202 is currently being evaluated in a first-in-human clinical study across
multiple solid tumor indications.
Undisclosed Programs
Dren Bio’s versatile platform has yielded a deep pipeline of
preclinical programs across various
therapeutic areas including oncology, immunology, and neurology.